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should take caution when mapping EQ-5D values from algorithms that have not 
been externally validated, especially where these algorithms have used clinical 
outcomes or disease-specific measures of health-related quality of life. Our results 
suggest that mapping from generic outcome measures might be reasonable.
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Objectives: The Mini-International Neuropsychiatric Interview (M.I.N.I.) is a short, 
structured diagnostic interview, developed by psychiatrists and clinicians in the 
USA and Europe, for DSM-IV and ICD-10 psychiatric disorders. The objectives of our 
study were: 1) To determine if the psychiatric terms used in the M.I.N.I. are trans-
latable worldwide, especially in non-western countries, and 2) To review strategies 
used to culturally adapt psychiatric terms. MethOds: We reviewed the records 
of all linguistic validation projects involving the M.I.N.I. Results: We retrieved 
67 language versions, representing 47 countries. The analysis of the translations’ 
content revealed three types of results, depending on the existence (or not) of cor-
responding psychiatric terminology in the target languages. The standard meth-
odology (forward/backward and clinician review) was used in all countries and 
adapted, depending on the context. In all western and westernized countries (e.g., 
Europe, Russia, etc., totaling 49 languages), the psychiatric terms used in the M.I.N.I. 
were easily translated (i.e., existence of an agreed-upon corresponding terminol-
ogy). In languages where psychiatric terms do not exist (e.g., certain Sub-Saharan 
languages), all the clinician-directed parts (titles and clinician-directed instruc-
tions/algorithms), which are capitalized in the original instrument, were left in 
English, and the patient-directed parts were translated in the target languages. In 
languages where there is a partially agreed-upon terminology (e.g., Thai), the titles 
as well as the algorithms were translated with corresponding English equivalents 
between brackets, when necessary. Moreover, in order to follow the typographical 
conventions of the M.I.N.I., in languages with no capital letters (such as Kannada 
or Malayalam), the translations used bigger font size. cOnclusiOns: This review 
showed that terms used to describe psychiatric disorders had no equivalents in 
some countries, especially in Africa. Translation was not always possible and was 
even judged to be culturally and linguistically irrelevant in countries where psy-
chiatry is only taught in English.
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Objectives: Sawicki questionnaire is a 32-item specific measure for the evalu-
ation of the change in the measure of the Quality of Health Related Life (HRQOL) 
experienced by patients treated by Novel Oral Anticoagulants (NOACs) versus tra-
ditional Oral Anticoagulant Therapies (OAT). The objective of this research focuses 
on the application of the Rasch model in selecting the most appropriate items of 
Sawicki questionnaire. MethOds: Sample was composed of 689 Atrial Fibrillation 
(AF) patients in whom an attempt of electrical or pharmacological cardioversion 
was scheduled within a 4 months inclusion period from baseline (CARDIOVERSE 
study). Data were analyzed with WinSteps version 3.75 using the Rasch Partial 
Credit Model. Statistical criteria taken into account for the selection of those 
items with better psychometric properties were: model-fit and separation statis-
tics, Differential Item Functioning (DIF), unexpected responses and item content. 
The results were compared with those of the original version of the question-
naire in CARDIOVERSE sample. Results: Misfiting items were deleted, resulting in 
a 12 items version rated on a 4-point Likert-scale. This short form of the ques-
tionnaire showed good model fit and represented an accurate measure of the 
construct. Infit MNSQ ranged from 0.90 to 1.15 (M= 1.02; SD= 0.09) and outfit MNSQ 
ranged from 0.90 to 1.18 (M= 1.02; SD= 0.08). Person separation index and item 
reliability were 2.11 and 0.99 respectively and item-person map showed that the 
test was on-target and covered the wide range of the ability scale. Finally, the 
criterion validity of the short version by age, sex and risk groups was similar to 
the original version of the questionnaire. cOnclusiOns: Short version of Sawicki 
questionnaire has adequate psychometric properties in terms of goodness-of-
fit-test and reliability. This version makes it possible to have a new short and 
appropriate HRQoL measure for the study of the effect in QoL experienced by 
patients treated by NOACs.
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Objectives: To test convergent-discriminant validity of quality of life (QOL) 
impact attributions to arthritis and respiratory conditions using the multitrait-
multimethod (MTMM) approach. MethOds: Chronically-ill adults (N= 601) with 
osteoarthritis (OA) and respiratory (asthma, COPD) disease completed Internet-
based surveys. Ages ranged from 18-93 (median= 58), 66.5% female and 20.7% non-
white. QOL impact was measured using 3 methods: QOL Disease Impact Scale 
(QDIS) and disease severity with specific attribution to each condition, specific 
worse cognitive function. Fifteen items had responses with ≥ 35% frequency and 
three items (turning a key, recreational activities with force, recreational activities 
with moving arm freely) had responses with ≥ 50% frequency. cOnclusiOns: 
Patients had no complaints about understanding or difficulty of the adapted ver-
sion of the questionnaire. Still, there were some items with missing answers (most 
often - sexual activity). Although, we provide some evidence of content validity, 
additional testing for the retention of psychometric properties of the translated 
questionnaire is recommended.
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Objectives: For models that simulate patients over a long span, such as from birth 
to life expectancy, the baseline HRQoL can be incorporated. Typically this means 
that younger people have a higher utility than older people. The aim of this study 
was to investigate the impact of including age-specific baseline utilities in a model 
that simulated women at elevated risk of developing breast cancer from ages 20 to 
85. MethOds: A model was developed to evaluate the impact on costs and benefits 
of breast cancer surveillance in a population of women with a BRCA1 mutation. 
Women were modelled from age 20 to 85. QALY reductions were associated with the 
treatment of cancer and were stage-specific. The model was evaluated incorporat-
ing age-specific baseline QALYs and also where all ages had a baseline QALY of 1. 
The impact of age-specific baseline QALY inclusion was evaluated in terms of the 
ICERs for different surveillance strategies. Results: The incremental cost of each 
intervention and the interventions included in the cost-effectiveness efficiency 
frontier were unaffected by the choice of baseline HRQoL. However, both the average 
and incremental cost-effectiveness ratios were changed. For interventions on the 
cost-effectiveness efficiency frontier, all ICERs were less than € 100,000/QALY when 
age-specific baseline HRQoL values were used. ICERs reduced by an average € 11,520 
when a uniform baseline HRQoL was used. cOnclusiOns: The use of age-specific 
baseline HRQoL in a cost-effectiveness model needs to be carefully considered. 
Inclusion of age-specific baseline HRQoL can favour interventions with an impact 
at a younger age. Whether age-specific or uniform baseline data are used in a model, 
the alternative should be considered in a sensitivity analysis.
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Objectives: To estimate EQ-5D-5L crosswalk value set for Poland, based on 
Crosswalk methodology developed by EuroQol Group. MethOds: Based on the data 
from 3691 respondents from 6 European countries, EuroQol Group has developed 
a method of obtaining interim values sets for the EQ-5D-5L by means of map-
ping to the available EQ-5D-3L values sets (“crosswalk” methodology). A significant 
part of the data in this study came from Polish respondents (n= 972; 26.3%). Poland 
is the first Central European country with EQ-5D-3L time trade-off based social 
values set published. In order to obtain interim EQ-5D-5L values set, we applied 
Crosswalk methodology, developed by EuroQol Group, to available Polish EQ-5D-3L 
values set. Results: Estimated Polish values for 3125 EQ-5D-5L health states will 
be presented. Both, EQ-5D-5L and EQ-5D-3L values sets have the same range (from 
-0.523 to 1.000), but different means (0.448 vs. 0.380) and medians (0.483 vs. 0.403), 
respectively. Participation of states worse than dead is less in EQ-5D-5L (5.38%), 
than in EQ-5D-3L (13.17%) values set. cOnclusiOns: As long as value set based on 
preferences directly elicited from representative Polish general population sample 
is not available, estimated crosswalk values set should be used in EQ-5D-5L studies 
in Poland in order to calculate health state utilities.
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Objectives: Existing studies exploring the validity of using mapping algorithms 
to predict utilities in external datasets have found mixed results. We apply a series 
of published EQ-5D mapping algorithms to individual patient level data from a 
trial which in fact collected this outcome, with a view to assess the impact of 
using predicted versus actual EQ-5D values on the results of a cost-effectiveness 
model. MethOds: The RITA-3 trial compared early interventional strategy for 
patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) against 
a conservative strategy. EQ-5D data were collected at baseline, 4 months, 12 
months and yearly thereafter. A range of other clinical and quality of life out-
comes were also collected including the Seattle Angina Questionnaire (SAQ), 
SF-36 and the Canadian Cardiovascular Society (CCS) Functional Classification of 
Angina. Using mapping algorithms found in the published literature, we predicted 
EQ-5D scores using these outcome measures. We then explored what effect the 
predicted utilities had upon cost-effectiveness estimates in a model compared 
to those with the actual EQ-5D data. The comparisons were made across five 
patient subgroups. Results: The cost-effectiveness estimates varied according to 
the original outcome measure used to map and the patient subgroup. The EQ-5D 
values predicted using CCS scores produced cost-effectiveness estimates much 
higher than those with the actual EQ-5D data in the trial, whilst the estimates 
using EQ-5D values predicted using SAQ scores were lower. The values predicted 
using SF-36 scores gave cost-effectiveness estimates very similar to those with 
the EQ-5D data, irrespective of the patient subgroup. cOnclusiOns: Analysts 
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Objectives: To develop a short questionnaire measuring health-related quality of 
life (HRQoL) in patients with chronic wounds. MethOds: Three validated instru-
ments assessing HRQoL in chronic wounds, the Freiburg Life Quality Assessment 
for wounds (FLQA-w), the Cardiff Wound Impact Schedule (CWIS), and the Würzburg 
Wound Score (WWS), were filled in by 154 leg ulcer patients in a prospective 
study under routine care. For implementation in the new, shorter questionnaire 
Wound-QoL, those of all 92 items were selected that covered the core content of 
the three questionnaires and showed good psychometric properties (e. g. num-
ber of missing values, inter-item correlations). Internal consistency, convergent 
validity regarding four generic HRQoL measures such as the EQ-5D, and respon-
siveness of the Wound-QoL were analysed using the longitudinal study data on 
the selected items (so-called virtual validation). Subscales were determined with 
factor analysis. Item, instruction, and response scale wording of the Wound-QoL 
were harmonized. Results: Seventeen items were included in the Wound-QoL 
questionnaire which could be attributed to three subscales on everyday life, body, 
and psyche. Both global score and subscale scores were internally consistent with 
Cronbach’s alpha values between 0.71 and 0.91. The global score showed significant 
convergent validity (r= 0.48 to 0.69, depending on the criterion) and responsive-
ness regarding change in generic HRQoL (r= 0.18 to 0.52); the same was true for 
the subscale scores. cOnclusiOns: The Wound-QoL for measurement of HRQoL 
in chronic wounds proved to be internally consistent, valid, and responsive in the 
virtual validation analysis.
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Objectives: To develop an algorithm for mapping of disease-specific health related 
quality of life scores to the EQ-5D utility index for patients with PD. MethOds: 
EQ-5D and Parkinson’s disease Questionnaire (PDQ) data were obtained for 117 
UK PD patients (HY stages 1-4) via a cross-sectional survey of practicing clinicians 
and their patients. The EQ-5D utility index (UK Tariff) was regressed on PDQ-39/
PDQ-8 summary indices (SI) and PDQ-39 domains/PDQ-8 questions using OLS 
regression. Analysis on PDQ-39 domains/PDQ-8 questions was repeated using 
OLS with backward elimination. Two-part models (TPM) were conducted on PDQ-
39/8 SI and domains/questions respectively consisting of a logistic regression on 
whether EQ-5D< 1 followed by either OLS, GLM with gamma distribution and log 
link or identity link functions and GLM with Gaussian distribution with log link 
for the remainder. Mapping equations were used to predict utilities which were 
subsequently compared to those observed. Models were compared using RMSE 
values. Results: Compared to simple OLS [RMSE 0.1685-0.1924], a model with back-
ward elimination of variables did not improve predictive power. Out of the TPMs the 
best fitting models were GLM with gamma distribution and identity link function 
[RMSE 0.1666-0.1929] and GLM with Gaussian distribution and log link function 
[RMSE 0.1683-0.1912]. All models produced better results utilising the domains of 
PDQ-39 or individual questions of PDQ-8 than with the SI. cOnclusiOns: All map-
ping algorithms estimated utilities for patients with HY stage 1-4 with reasonable 
accuracy. Therefore, mapping functions reported could be used for predicting EQ-5D 
scores from either PDQ-39 or PDQ-8 when EQ-5D data were not collected. However, 
simple OLS, TPMs with gamma family and identity function and Gaussian family 
and log functions resulted in the best prediction and the smallest RMSE values. 
Further validation is needed to ascertain whether these mapping functions perform 
well for more advanced patients in HY stage 5.
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Objectives: Patients with Systemic Lupus Erythematosus (SLE) experience unmet 
medical needs and many inflammatory symptoms resulting in humanistic and 
economic burden. This study aimed to create a conceptual model of patient and eco-
nomic burden, and review patient-reported outcomes (PROs) used to measure such 
concepts in SLE clinical trials. MethOds: An SLE conceptual model was developed 
from structured review of published articles from 2007-June 2012 identified from 
literature databases (MEDLINE, PsycINFO, EconLit) plus other sources (PROLabels, 
FDA/EMA websites, Clinicaltrials.gov). PROs targeting key symptom/impact were 
identified from the literature. In the context of FDA guidance, the PROs were subject 
to in-depth review and assessed for face and content validity, and psychomet-
ric properties to determine appropriateness for use in SLE trials. Results: Pain, 
fatigue, cognition, daily activities, emotional well-being, physical/social functioning, 
and work productivity were in the conceptual model identified as key SLE concepts. 
Of the 63 articles reviewed, 31 reported PRO data. From these and the other sources, 
14 PROs were selected for review including SLE-specific health-related quality of life 
(HRQoL) measures (n= 3), work productivity (n= 1), and generic measures of fatigue 
(n= 3), pain (n= 2), depression (n= 2) and HRQoL (n= 3) as these were deemed salient 
for patients with SLE in the literature. The FACIT-Fatigue, BPI-SF (pain) and LupusQoL 
demonstrated the strongest face validity, conceptual coverage and psychometric 
properties measuring key concepts in the conceptual model. All PROs reviewed, 
symptoms (joint pain, shortness of breath), and generic physical (PCS) and men-
tal (MCS) summary measures (SF-36). The resulting 10X10 correlation matrix (3 
disease-specific, 2 generic) for each disease was evaluated to test convergent 
validity (correlations > 0.40 between different methods of measuring the same 
disease) and discriminant validity (significantly lower correlations between dif-
ferent diseases measured by the same method). The MTMM matrix was also ana-
lyzed using principal component analysis (PCA) to test for disease versus methods 
factors. Results: The MTMM matrix yielded strong evidence that patients dis-
criminated the impact of one condition from the other. In support of convergent 
validity, disease specific QOL impact, severity and symptom measures (joint pain 
for OA, SOB for respiratory) correlated substantially for asthma (0.516 - 0.765) 
and OA (0.465 - 0.774). In support of discriminant validity, different diseases 
measured by the same method correlated significantly lower (0.264 - 0.286). 
PCA yielded two disease-specific factors (OA and respiratory) with high loadings 
across methods for OA (0.748 - 0.871 and respiratory (0.687 - 0.890) and low sec-
ondary loadings (0.085 - 0.262). Generic PCS and MCS measures correlated lower 
than disease-specific measures, as hypothesized. 2-method (QOL impact, sever-
ity) MTMM validations replicated these results across 37 pairs of over-sampled 
comorbid conditions. cOnclusiOns: Results strongly support the convergent-
discriminant validity of survey measures of QOL impact based on attributions to 
OA and respiratory disease and suggest that disease-specific attributions may 
improve the validity of QOL impact attributions for other common pairs of comor-
bid conditions.
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Objectives: Mapping algorithms can translate disease-specific or generic 
health-related quality of life measurements into values obtained from prefer-
ence-based instruments such as the EuroQol 5-dimension questionnaire (EQ-
5D). The Oxford Hip Score (OHS) is a disease-specific instrument widely used by 
orthopaedic surgeons to assess outcomes from hip surgery. There is an algorithm 
for estimating mean EQ-5D scores from the OHS, but this was developed using 
early response mapping methods and has limited external validation. We have 
developed a new mapping algorithm to translate OHS results into EQ-5D domain 
responses and utilities in a large UK dataset using direct and response mapping 
methods. MethOds: OHS and EQ-5D responses were extracted from the publicly 
available National Patient Reported Outcomes Measures (PROMs) database. The 
sample of complete data pairs (n= 126 862) was split into estimating (n= 51 800, 
years 2009–10) and external validation (n= 75 062, years 2010–12) samples. EQ-5D 
utilities were estimated directly using ordinary least squares regression and two-
part models. EQ-5D responses were estimated using ordered and multinomial logit 
models. For the two-part and the multinomial logit models, the expected value 
method was used to calculate utilities. Performance was evaluated using mean 
square error (MSE) and mean absolute error (MAE). Results: The two-part models 
and the ordered or multinomial regressions performed better than ordinary least 
square regression. In external validation, the MSE (MAE) was 0.0319 (0.1286) for 
the two-part model and 0.0315 (0.1249) for response mapping. For EQ-5D index 
values > 0.5 (better health states), response mapping predictions had a slightly 
smaller MSE and MAE than direct method predictions. Both indirect and direct 
approaches predicted higher MSE and MAE when EQ-5D < 0.5. cOnclusiOns: 
Response mapping between OHS and EQ-5D was similar or slightly more predic-
tive than direct mapping. Further research is needed to improve the performance 
of these techniques in poorer health states.
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Objectives: A large number of quality of life (QoL) values for patients with coro-
nary heart disease (CHD) are available in the literature. From the abundance of QoL 
values in CHD, only preference-based values can be directly applied in cost-utility 
analysis (CUA). In this study we performed a multivariate meta-regression analysis 
of the preference-based QoL values in CHD. Our aim was to obtain a summarized 
QoL estimate while accounting for study-level covariates and for the correlation 
between multiple outcomes both within and between studies. MethOds: Studies 
were considered eligible for this analysis if they reported mean QoL values, standard 
deviations and the instrument for measuring QoL (e.g. EQ-5D, SF-6D). Additionally, 
studies reporting separate values of SF-36 and SF-12 QoL instruments were included. 
The scores of the SF-36 and SF-12 QoL were mapped onto EQ-5D and SF-6D values. 
Mapped preference-based values were added to the base-case data set that con-
sisted only of published preference-based QoL values. Finally, a multivariate meta-
regression model was used in order to estimate pooled, instrument-specific QoL 
in CHD. Results: Our systematic search identified 35 eligible studies reporting 43 
preference-based QoL values in CHD as well as 46 studies reporting QoL scores of 
SF-36 and SF-12. Following instrument-specific QoL estimates were obtained when 
conducting the analysis on the base-case data set: 0.77 (EQ-5D UK), 0.79 (EQ-5D 
US), 0.65 (SF-6D), 0.85 (15D), 0.44 (HUI3) and 0.63 (QWB). Age was the only study-
level covariate that showed an influence on instrument-specific QoL estimates. 
Significant heterogeneity was observed when the analysis was conducted on the 
expanded data set. cOnclusiOns: This study represents the first meta-analysis 
of QoL in CHD. Given the abundance of QoL values in CHD on the one hand and 
the requirement for single, accurate QoL values in CUA on the other hand, pooled 
estimates of QoL could be highly applicable in CUA.
